PHOENIX and VANCOUVER, British Columbia, Dec. 13, 2016 -- Eternity Healthcare Inc. (OTC:ETAH), is pleased to announce completion of its Lenis®, Needle-Free Injection development phase. “This is a significant milestone for our company as it now means we can proceed towards regulatory approval,” said Hassan Salari, President & CEO. “The device surpassed all original design goals and with proven reliability during testing.”
The Lenis® injector underwent rigorous testing, exceeding 1000 individual tests, proving not only reliable but economical. The Lenis® Needle-Free Injection system has four major components that each will require individual testing to satisfy regulatory approval. The main component of the system is the injector which uses a high powered spring loaded bursting mechanism.
“We believe Lenis® will revolutionize medical injections as they can now be done without patient fear of needles and with a substantial reduction in cost per injection. The injection systems market is currently estimated at $9.8 Billion for 2016 and expected to grow at 15.5% until reaching $20.17 Billion in size by 2021. Unlike our competition, our design allows for delivery of larger doses, meaning Lenis® could be used with traditional needle and syringes used worldwide. We’re confident we have a disruptive technology,” said Hassan Salari.
Needle-Free Injection System Applications
The needle-Free Injection system can be used for a vast variety of injectable medications, and supplements. These include injection of Insulin for diabetes, injection of vaccines such as flu vaccine and many others, injection of steroids, vitamins, human growth hormones, infertility medications and a vast number of cancer drugs. Further applications such as injection of epinephrine might replace Auto-Injectors such as Mylan’s Epipen®.
Benefits of Needle-Free Injection System
The Needle-Free injection system has many advantages over the existing needle injection. These include being environmentally friendly and reducing the risk of accidental poking and cross contamination. Further, the Needle-Free Injection device is good for children and people with needle phobia. It is easy to discard the used syringes as well as to recycle them.
About Eternity Healthcare
Eternity Healthcare or the “Company” (OTC:ETAH) is a healthcare company with technologies in medical devices. Our most advanced product is a Needle-Free Injection system known as Lenis®. Our products are targeted for use by the healthcare professionals, physicians and consumers directly. More information on Eternity Healthcare, visit the Company’s website; www.eternityhealthcare.com
Social Networks:
Twitter.com/EternityHealth
Facebook.com/EternityHealthcare
Safe Harbor Statement
This release includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as ETAH or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements herein that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
Company Contact: Dr. Hassan Salari President & CEO (604) 324 -1113 [email protected] [email protected]


Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Apple Turns 50: From Garage Startup to AI Crossroads
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
First Western Ship Transits Strait of Hormuz Since Iran War Began
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 



